Teva Pharmaceutical Industries Limited financials
$39.81+2.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B | $16.66B | $16.89B | $18.27B | $21.85B | $21.90B |
| Gross profit | $8.94B | $8.06B | $7.65B | $6.97B | $7.59B | $7.73B | $7.54B | $8.30B | $10.62B | $11.65B |
| Gross margin | 51.8% | 48.7% | 48.3% | 46.7% | 47.8% | 46.4% | 44.6% | 45.4% | 48.6% | 53.2% |
| Operating income | $2.16B | -$303.0M | $433.0M | -$2.20B | $1.72B | -$3.57B | -$444.0M | -$1.64B | -$17.48B | $1.39B |
| Net income | $1.41B | -$1.64B | -$559.0M | -$2.45B | $417.0M | -$3.99B | -$999.0M | -$2.40B | -$16.52B | $68.0M |
| Net margin | 8.2% | −9.9% | −3.5% | −16.4% | 2.6% | −24.0% | −5.9% | −13.1% | −75.6% | 0.3% |
| Diluted EPS | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 | $-3.64 | $-0.91 | $-2.35 | $-16.26 | $0.07 |
| EBITDA | $4.93B | $4.44B | $4.40B | $2.02B | $3.81B | $4.66B | $4.52B | $5.00B | $7.30B | $6.13B |
| Operating cash flow | $1.65B | $1.25B | $1.37B | $1.59B | $798.0M | $1.22B | $748.0M | $2.45B | $2.23B | $3.89B |
| Free cash flow | $1.15B | $749.0M | $842.0M | $1.04B | $236.0M | $638.0M | $223.0M | $1.79B | $1.35B | $2.99B |
| Diluted shares | 1,163.0M | 1,131.0M | 1,119.0M | 1,110.0M | 1,107.0M | 1,095.0M | 1,091.0M | 1,021.0M | 1,016.0M | 961.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.56B | $3.30B | $3.23B | $2.80B | $2.17B | $2.18B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $16.81B | $17.78B | $19.83B | $21.21B | $23.04B | $25.92B |
| Total assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B | $50.64B |
| Total liabilities | $32.83B | $33.61B | $35.35B | $35.41B | $36.42B | $39.58B |
| Shareholders' equity | $7.91B | $5.38B | $8.13B | $8.60B | $11.24B | $11.06B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology